妊娠期抗病毒预防阻断HBV母婴传播的有效性与安全性:系统综述与Meta分析
该系统综述与Meta分析纳入129项研究,评估妊娠期抗病毒预防对阻断HBV母婴传播的效果。
要点
- 妊娠期抗病毒预防可显著降低HBV母婴传播风险。
- 未发现婴儿或母亲安全性结局风险增加。
核心结论
- 围产期抗病毒预防对降低HBV母婴传播风险高度有效,支持2020年WHO推荐妊娠期使用替诺福韦预防HBV母婴传播。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Embase、Scopus、CENTRAL、CNKI和Wanfang,纳入随机对照试验和非随机研究,检索至2019年3月28日。
- 共纳入129项研究(157篇文章),评估替诺福韦300 mg(19项研究,1092名母亲和1072名婴儿)、拉米夫定100-150 mg(40项研究,2080名母亲和2007名婴儿)和替比夫定600 mg(83项研究,6036名母亲和5971名婴儿)。
- 主要终点为婴儿6-12月龄时HBsAg阳性的母婴传播,安全性通过合并风险差评估。
主要发现
- 未发现围产期抗病毒预防后婴儿或母亲安全性结局风险增加。
关键数值与推荐
- 纳入研究为妊娠期慢性HBV感染孕妇,使用阿德福韦、恩曲他滨、恩替卡韦、拉米夫定、替比夫定、替诺福韦艾拉酚胺富马酸盐或替诺福韦二吡呋酯中任一抗病毒药。
- 结局需报告婴儿6-12月龄时HBsAg阳性或HBV DNA阳性或两者兼有的母婴传播,以及任何婴儿或母亲不良事件。
临床怎么用
- 对于高母婴传播风险且婴儿免疫预防不足的HBV感染孕妇,可考虑妊娠期使用替诺福韦等抗病毒预防以降低母婴传播风险。
局限性
- 检索截止2019年3月28日,未纳入此后发表的研究。
- 纳入研究以非随机研究为主,随机对照试验证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To eliminate mother-to-child transmission (MTCT) of hepatitis B virus (HBV), peripartum antiviral prophylaxis might be required for pregnant women infected with HBV who have a high risk of MTCT despite infant immunoprophylaxis. We aimed to determine the efficacy and safety of peripartum antiviral prophylaxis to inform the 2020 WHO guidelines. METHODS: In this systematic review and meta-analysis, we searched PubMed, Embase, Scopus, CENTRAL, CNKI, and Wanfang for randomised controlled trials and non-randomised studies of peripartum antiviral prophylaxis versus placebo or no prophylaxis, with no language restriction, published from database inception until March 28, 2019. We used search terms covering HBV, antiviral therapy, and pregnancy. We included studies that enrolled pregnant women with chronic infection with HBV who received antiviral prophylaxis anytime during pregnancy; that included any of the following antivirals: adefovir, emtricitabine, entecavir, lamivudine, telbivudine, tenofovir alafenamide fumarate, and tenofovir disoproxil fumarate; and that reported the following outcomes: MTCT, indicated by infant HBsAg positivity or HBV DNA positivity, or both, at age 6-12 months, and any infant or maternal adverse events. Two reviewers independently extracted data. Our primary endpoint was MTCT based on infant HBsAg positivity. We assessed pooled odds ratios (ORs) of the efficacy of peripartum antiviral prophylaxis to reduce the risk of MTCT. We assessed safety of prophylaxis by pooling risk differences. The protocol for the systematic review was pre-registered in PROSPERO, CRD42019134614. FINDINGS: Of 7463 articles identified, 595 articles were eligible for full-text review and 129 studies (in 157 articles) were included. The following antivirals were assessed in the meta-analysis: tenofovir disoproxil fumarate 300 mg (19 studies, with 1092 mothers and 1072 infants), lamivudine 100-150 mg (40 studies, with 2080 mothers and 2007 infants), and telbivudine 600 mg (83 studies, with 6036 mothers and 5971 infants). The pooled ORs for randomised controlled trials were similar, at 0·10 (95% CI 0·03-0·35) for tenofovir disoproxil fumarate, 0·16 (0·10-0·26) for lamivudine, and 0·14 (0·09-0·21) for telbivudine. The pooled ORs in non-randomised studies were 0·17 (0·10-0·29) for tenofovir disoproxil fumarate, 0·17 (0·12-0·24) for lamivudine, and 0·09 (0·06-0·12) for telbivudine. We found no increased risk of any infant or maternal safety outcomes after peripartum antiviral prophylaxis. INTERPRETATION: Peripartum antiviral prophylaxis is highly effective at reducing the risk of HBV MTCT. Our findings support the 2020 WHO recommendation of administering antivirals during pregnancy, specifically tenofovir disoproxil fumarate, for the prevention of HBV MTCT. FUNDING: World Health Organization.
引用
- Funk AL, Lu Y, Yoshida K, et al. Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis. Lancet Infect Dis. 2020. PMID: 32805200. doi:10.1016/S1473-3099(20)30586-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。